Letrozole Torrent Pharma (Uk)

Letrozole, the active ingredient in Letrozole Torrent Pharma (Uk), is a aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine treatment of postmenopausal hormone receptor‑positive breast cancer, reducing estrogen‑driven tumor growth.

GNH USA supplies Letrozole Torrent Pharma (Uk) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Letrozole acts on estrogen‑dependent breast cancer pathways and is indicated for several stages of the disease. - Postmenopausal hormone receptor‑positive breast cancer: reduces risk of recurrence and disease progression. - Adjuvant treatment of early‑stage breast cancer: improves disease‑free survival after surgery. - Metastatic breast cancer: slows tumor growth and extends overall survival.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in joints or muscles. - Fatigue: persistent tiredness. - Nausea: feeling of sickness or urge to vomit.

Serious or Rare Side Effects: - Severe liver injury: elevated liver enzymes or hepatitis. - Bone fracture: increased risk due to reduced bone density. - Pulmonary embolism: blood clot in the lungs. - Allergic reaction: rash, swelling, or difficulty breathing.

Before initiating Letrozole therapy, several safety considerations should be addressed. - Bone health monitoring: assess bone mineral density regularly. - Liver function assessment: check hepatic enzymes prior to and during treatment. - Cardiovascular risk evaluation: review history of thromboembolic events. - Concomitant medication review: avoid drugs that may interfere with aromatase inhibition. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Letrozole can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce Letrozole plasma levels. - Estrogen‑containing hormone therapy: antagonizes therapeutic effect. - Tamoxifen: competitive estrogen receptor modulation.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole): may increase Letrozole exposure. - Selective serotonin reuptake inhibitors: potential additive effect on QT interval. - Warfarin: possible alteration of anticoagulant control.